• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Why Motorsport Games Shares Are Trading Lower By Over 10%; Here Are 20 Stocks Moving Premarket

    3/27/23 7:59:15 AM ET
    $ALLR
    $BGRY
    $BOXD
    $BRDS
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Industrial Machinery/Components
    Industrials
    Get the next $ALLR alert in real time by email

    Gainers

    • Coeptis Therapeutics Holdings, Inc. (NASDAQ:COEP) shares rose 38.5% to $2.05 in pre-market trading after gaining 8% on Friday.
    • First Republic Bank (NYSE:FRC) gained 25.5% to $15.51 in pre-market trading. U.S. authorities plan to give First Republic Bank more time to ramp up its balance sheet and have yet to decide on what support, if any, to provide to the troubled lender, according to Bloomberg.
    • Berkshire Grey, Inc. (NASDAQ:BGRY) gained 18.4% to $1.35 in pre-market trading as the company entered into definitive merger agreement with SoftBank Group for a go-private transaction.
    • Silvergate Capital Corporation (NYSE:SI) climbed 14% to $1.96 in pre-market trading. Silvergate Capital shares jumped 52% on Friday as traders circulated a rumor that a crypto exchange is trying to buy the company's trade processing technologies.
    • Allarity Therapeutics, Inc. (NASDAQ:ALLR) rose 11.1% to $2.99 in pre-market. Allarity Therapeutics shares dropped 32% on Friday after the company announced a reverse stock split of its common stock.
    • G Medical Innovations Holdings Ltd (NASDAQ:GMVD) gained 9.1% to $2.16 in pre-market trading after gaining 15% on Friday.
    • Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) shares rose 8.9% to $6.02 in pre-market trading. Iovance Biotherapeutics completed Biologics License Application submission for Lifileucel in advanced melanoma.
    • CytomX Therapeutics, Inc. (NASDAQ:CTMX) rose 8.2% to $1.84 in pre-market trading. CytomX Therapeutics is expected to report full year 2022 financial results on Monday, March 27, 2023, after the closing bell.
    • PacWest Bancorp (NASDAQ:PACW) shares rose 7.9% to $10.30 in pre-market trading. Pacwest Bancorp said, consistent with its announcement on March 17, 2023, the bank continues to benefit from solid liquidity and stabilized deposit balances, with over $11.4 billion in available cash as of March 20, 2023, which exceeds total uninsured deposits of $9.5 billion as of March 20, 2023.
    • Faraday Future Intelligent Electric Inc. (NASDAQ:FFIE) shares rose 7.6% to $0.4008 in pre-market trading. Faraday Future recently posted a Q4 loss of $0.32 per share.

    Losers

    • Virios Therapeutics, Inc. (NASDAQ:VIRI) fell 12.1% to $0.3911 in pre-market trading after jumping around 44% on Friday.
    • Aurora Mobile Limited (NASDAQ:JG) shares dropped 10.7% to $0.5501 in pre-market trading. Aurora Mobile recently signed a strategic agreement with Rainbow Digital Commercial.
    • Motorsport Games Inc. (NASDAQ:MSGM) fell 10.3% to $6.00 in pre-market trading after the company posted downbeat results for its fourth quarter on Friday.
    • Greenbrook TMS Inc. (NASDAQ:GBNH) fell 8.3% to $0.9439 in pre-market after jumping 94% on Friday. The company recently announced $8.25 million equity and debt financings.
    • Bird Global, Inc. (NASDAQ:BRDS) fell 8.2% to $0.1375 in pre-market trading after gaining over 5% on Friday.
    • Boxed, Inc. (NYSE:BOXD) shares fell 7.1% to $0.2259 in pre-market trading after dropping over 29% on Friday.
    • NeuBase Therapeutics, Inc. (NASDAQ:NBSE) fell 7% to $0.16 in pre-market trading after dropping 9% on Friday.
    • SMX (Security Matters) Public Limited Company (NASDAQ:SMX) fell 6.7% to $1.12 in pre-market trading after declining 7% on Friday.
    • Pear Therapeutics, Inc. (NASDAQ:PEAR) shares fell 6.8% to $0.27 in pre-market trading after jumping over 15% on Friday.
    • Blue Star Foods Corp. (NASDAQ:BSFC) fell 6.3% to $0.1632 in pre-market trading after gaining around 12% on Friday.

    Now Read This: S&P 500 Records Weekly Gain, Market Volatility Increases

    Get the next $ALLR alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ALLR
    $BGRY
    $BOXD
    $BRDS

    CompanyDatePrice TargetRatingAnalyst
    CytomX Therapeutics Inc.
    $CTMX
    3/16/2026$12.00Neutral → Overweight
    Analyst
    Iovance Biotherapeutics Inc.
    $IOVA
    2/25/2026$5.00Mkt Perform → Mkt Outperform
    Citizens
    CytomX Therapeutics Inc.
    $CTMX
    1/20/2026$10.00Buy
    Guggenheim
    CytomX Therapeutics Inc.
    $CTMX
    9/22/2025$6.00Overweight
    Cantor Fitzgerald
    CytomX Therapeutics Inc.
    $CTMX
    9/17/2025$3.50Overweight
    Barclays
    Shoulder Innovations Inc.
    $SI
    8/25/2025$20.00Buy
    Goldman
    Shoulder Innovations Inc.
    $SI
    8/25/2025$23.00Buy
    BTIG Research
    Shoulder Innovations Inc.
    $SI
    8/25/2025$18.00Overweight
    Piper Sandler
    More analyst ratings

    $ALLR
    $BGRY
    $BOXD
    $BRDS
    SEC Filings

    View All

    Coeptis Therapeutics Holdings Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

    8-K - Coeptis Therapeutics Holdings, Inc. (0001759186) (Filer)

    4/7/26 9:45:07 PM ET
    $COEP
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 6-K filed by SMX (Security Matters) Public Limited Company

    6-K - SMX (Security Matters) Public Ltd Co (0001940674) (Filer)

    4/7/26 5:15:03 PM ET
    $SMX
    Industrial Machinery/Components
    Technology

    SEC Form 6-K filed by SMX (Security Matters) Public Limited Company

    6-K - SMX (Security Matters) Public Ltd Co (0001940674) (Filer)

    4/6/26 7:30:12 AM ET
    $SMX
    Industrial Machinery/Components
    Technology

    $ALLR
    $BGRY
    $BOXD
    $BRDS
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Lee Hon Sang

    4 - Aurora Mobile Ltd (0001737339) (Issuer)

    4/1/26 6:32:25 AM ET
    $JG
    Computer Software: Programming Data Processing
    Technology

    SEC Form 4 filed by Lee Hon Sang

    4 - Aurora Mobile Ltd (0001737339) (Issuer)

    3/27/26 8:02:51 AM ET
    $JG
    Computer Software: Programming Data Processing
    Technology

    SEC Form 4 filed by Chu Yu-Waye

    4 - CytomX Therapeutics, Inc. (0001501989) (Issuer)

    3/19/26 6:41:25 PM ET
    $CTMX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ALLR
    $BGRY
    $BOXD
    $BRDS
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Coeptis Announces Approval of Z Squared Inc.'s Nasdaq Listing Application

    ~ Approval Marks Satisfaction of Key Closing Condition in Pending Merger ~ WEXFORD, Pa., April 07, 2026 (GLOBE NEWSWIRE) -- Coeptis Therapeutics Holdings, Inc. (NASDAQ:COEP) ("Coeptis" or the "Company"), a next-gen technology and biopharmaceutical company, today announced that Nasdaq has approved, subject to customary conditions and the closing of the proposed merger, the listing of the post-merger Company's common stock on the Nasdaq Global Market under the ticker symbol "ZSQR". The new listing is expected to become effective upon the closing of the proposed merger between the Company and Z Squared, Inc., pursuant to which Z Squared will become a wholly owned subsidiary of Coeptis and th

    4/7/26 12:05:56 PM ET
    $COEP
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Aurora Mobile Unveils 500% Efficiency Boost Case Study at Tourism × Web3 Summit 2026

    SINGAPORE, April 02, 2026 (GLOBE NEWSWIRE) -- Aurora Mobile Limited (NASDAQ:JG) ("Aurora Mobile" or the "Company"), a leading provider of customer engagement and marketing technology services, is pleased to announce that its Japanese subsidiary, Aurora Mobile Japan K.K., successfully participated as a sponsor and keynote speaker at the "Tourism × Web3 Summit 2026." The event served as a premier stage for the Company to demonstrate how its AI-driven capabilities are revolutionizing the tourism and Web3 sectors. Keynote Highlights: Redefining Engagement with an AI-First ApproachAkio Mitobe, CTO of Aurora Mobile Japan K.K., delivered a special pitch on the transformative impact of Engage

    4/2/26 7:00:00 AM ET
    $JG
    Computer Software: Programming Data Processing
    Technology

    Le Mans Ultimate Releases Version 1.3 Update, Introducing Circuit de Barcelona-Catalunya, Duqueine D09 LMP3 Race Car, New Track Layouts, Logitech Trueforce Support and Performance Improvements

    MIRAMAR, Fla., March 31, 2026 (GLOBE NEWSWIRE) -- Motorsport Games Inc. (NASDAQ:MSGM) ("Motorsport Games" or the "Company"), a racing game developer, publisher, and esports ecosystem provider of official motorsport racing series, today released version 1.3 of Le Mans Ultimate, delivering the final European Le Mans Series Season Pass content pack, significant new track layouts, native Logitech Trueforce and haptic feedback integration, substantial performance optimizations, and continued improvements to online competition systems. Version 1.3 completes the European Le Mans Series ("ELMS") Season Pass with the addition of the Duqueine D09, a third-generation LMP3 chassis powered by a twin-t

    3/31/26 9:00:00 AM ET
    $MSGM
    Computer Software: Prepackaged Software
    Technology

    $ALLR
    $BGRY
    $BOXD
    $BRDS
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    CytomX Therapeutics upgraded by Analyst with a new price target

    Analyst upgraded CytomX Therapeutics from Neutral to Overweight and set a new price target of $12.00

    3/16/26 11:34:14 AM ET
    $CTMX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Iovance Biotherapeutics upgraded by Citizens with a new price target

    Citizens upgraded Iovance Biotherapeutics from Mkt Perform to Mkt Outperform and set a new price target of $5.00

    2/25/26 7:38:09 AM ET
    $IOVA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Guggenheim initiated coverage on CytomX Therapeutics with a new price target

    Guggenheim initiated coverage of CytomX Therapeutics with a rating of Buy and set a new price target of $10.00

    1/20/26 9:23:09 AM ET
    $CTMX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ALLR
    $BGRY
    $BOXD
    $BRDS
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Financial Officer Points Jeffrey S. exercised 13,264 shares at a strike of $2.48 and bought $30,000 worth of shares (2,000 units at $15.00), increasing direct ownership by 27% to 70,785 units (SEC Form 4)

    4 - SHOULDER INNOVATIONS, INC. (0001699350) (Issuer)

    3/17/26 5:42:34 PM ET
    $SI
    Medical/Dental Instruments
    Health Care

    Director Buchholz Richard bought $14,840 worth of shares (1,000 units at $14.84), increasing direct ownership by 8% to 13,666 units (SEC Form 4)

    4 - SHOULDER INNOVATIONS, INC. (0001699350) (Issuer)

    3/17/26 5:34:29 PM ET
    $SI
    Medical/Dental Instruments
    Health Care

    CEO & Executive Chairman Ball Robert Joseph bought $33,392 worth of shares (2,200 units at $15.18), increasing direct ownership by 0.80% to 278,866 units (SEC Form 4)

    4 - SHOULDER INNOVATIONS, INC. (0001699350) (Issuer)

    3/17/26 5:31:09 PM ET
    $SI
    Medical/Dental Instruments
    Health Care

    $ALLR
    $BGRY
    $BOXD
    $BRDS
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    February 16, 2024 - FDA Approves First Cellular Therapy to Treat Patients with Unresectable or Metastatic Melanoma

    For Immediate Release: February 16, 2024 Today, the U.S. Food and Drug Administration approved Amtagvi, the first cellular therapy indicated for the treatment of adult patients with a type of skin cancer (melanoma) that is unable to be removed with surgery (unresectable) or has spread to other parts of the body (metastatic) that previously has been treated with other therapies (a PD-1 blocking antibody, and if B

    2/16/24 3:48:47 PM ET
    $IOVA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ALLR
    $BGRY
    $BOXD
    $BRDS
    Leadership Updates

    Live Leadership Updates

    View All

    Shoulder Innovations Appoints MedTech Veteran Drew Hykes to Board of Directors

    GRAND RAPIDS, Mich., March 2, 2026 /PRNewswire/ -- Shoulder Innovations, Inc. ("Shoulder Innovations") (NYSE:SI), a commercial-stage medical technology company exclusively focused on transforming the shoulder surgical care market, today announced the appointment of Drew Hykes to the company's Board of Directors ("Board") and as a member of the Compensation Committee, effective February 26, 2026. Concurrent with Mr. Hykes's appointment, Geoff Pardo will resign as an Independent Director from the Board.   "Drew is a proven healthcare leader, and we are thrilled to welcome him to S

    3/2/26 7:00:00 AM ET
    $SI
    Medical/Dental Instruments
    Health Care

    Cardiff Oncology Announces Executive Leadership Changes as it Transitions to Late-Stage Clinical Development

    SAN DIEGO, Jan. 27, 2026 (GLOBE NEWSWIRE) -- Cardiff Oncology, Inc. (NASDAQ:CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of cancers, today announced a leadership transition designed to support the Company's next phase of growth and advancement toward late-stage development and key clinical and corporate milestones. Mani Mohindru, PhD, a member of Cardiff Oncology's Board of Directors since 2021 and a seasoned biotech executive, has been appointed interim Chief Executive Officer, effective immediately. Mark Erlander, PhD, Chief Executive Officer, and James Levine, Chief Financial Officer, have stepped down from their res

    1/27/26 7:00:00 AM ET
    $CRDF
    $CTMX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Biotechnology: Pharmaceutical Preparations

    CytomX Therapeutics Appoints Rachael Lester as Chief Business Officer

    SOUTH SAN FRANCISCO, Calif., Oct. 20, 2025 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (NASDAQ:CTMX), a leader in the field of masked, conditionally activated biologics, today announced the appointment of Rachael Lester as Senior Vice President, Chief Business Officer. In this role, Ms. Lester will lead the Company's strategy and business development functions.   "Rachael brings a wealth of experience in strategic planning and business development across the biopharmaceutical industry and joins CytomX at a time when our platform and pipeline are well positioned to deliver meaningful advances in the treatment of many cancers," said Sean McCarthy, D.Phil., president, chief executive offic

    10/20/25 4:05:00 PM ET
    $CTMX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ALLR
    $BGRY
    $BOXD
    $BRDS
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Blue Star Foods Corp.

    SC 13G/A - Blue Star Foods Corp. (0001730773) (Subject)

    11/14/24 7:34:10 PM ET
    $BSFC

    Amendment: SEC Form SC 13G/A filed by Faraday Future Intelligent Electric Inc.

    SC 13G/A - FARADAY FUTURE INTELLIGENT ELECTRIC INC. (0001805521) (Subject)

    11/14/24 4:56:24 PM ET
    $FFIE
    Auto Manufacturing
    Consumer Discretionary

    Amendment: SEC Form SC 13G/A filed by Iovance Biotherapeutics Inc.

    SC 13G/A - IOVANCE BIOTHERAPEUTICS, INC. (0001425205) (Subject)

    11/14/24 4:50:30 PM ET
    $IOVA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ALLR
    $BGRY
    $BOXD
    $BRDS
    Financials

    Live finance-specific insights

    View All

    Le Mans Ultimate Releases Version 1.3 Update, Introducing Circuit de Barcelona-Catalunya, Duqueine D09 LMP3 Race Car, New Track Layouts, Logitech Trueforce Support and Performance Improvements

    MIRAMAR, Fla., March 31, 2026 (GLOBE NEWSWIRE) -- Motorsport Games Inc. (NASDAQ:MSGM) ("Motorsport Games" or the "Company"), a racing game developer, publisher, and esports ecosystem provider of official motorsport racing series, today released version 1.3 of Le Mans Ultimate, delivering the final European Le Mans Series Season Pass content pack, significant new track layouts, native Logitech Trueforce and haptic feedback integration, substantial performance optimizations, and continued improvements to online competition systems. Version 1.3 completes the European Le Mans Series ("ELMS") Season Pass with the addition of the Duqueine D09, a third-generation LMP3 chassis powered by a twin-t

    3/31/26 9:00:00 AM ET
    $MSGM
    Computer Software: Prepackaged Software
    Technology

    Allarity Therapeutics Reports Full Year 2025 Financial Results and Corporate Progress

         Strengthened financial position through disciplined cost management, with a year-end 2025 cash position of $14.7 million and runway into mid-2028Received FDA Fast Track designation for stenoparib, enabling accelerated development in advanced ovarian cancerDurable clinical benefit observed in ongoing stenoparib ovarian cancer study, including patients treated for nearly 30 months, with new Phase 2 protocol implementedExpansion of stenoparib development beyond ovarian cancer with the launch of a VA-funded Phase 2 combination study in recurrent small cell lung cancer TARPON SPRINGS, Fla., March 31, 2026 – Allarity Therapeutics, Inc. ("Allarity" or the "Company") (NASDAQ:ALLR), a Phase 2

    3/31/26 8:00:00 AM ET
    $ALLR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    CytomX Therapeutics Announces 2025 Financial Results and Provides Business Update

    - Announced Positive Data from Phase 1 Dose Expansion Study of varsetatug masetecan ("Varseta-M") EpCAM PROBODY® ADC in Patients with Advanced Colorectal Cancer (CRC) - - FDA interactions targeted for mid-year with goal to align on potential Varseta-M registrational trial design in late line CRC - - Varseta-M Phase 1 study evaluating combination with bevacizumab initiated; Phase 1b/2 chemotherapy combination study to be initiated by the end of 2026 - - Initial CX-801 PROBODY Interferon-alpha-2b Phase 1 combination data with KEYTRUDA® (pembrolizumab) in melanoma expected by the end of 2026 - - Company to host conference call today at 8 a.m. ET / 5 a.m. PT - SOUTH SAN FRANCISCO, Calif., M

    3/16/26 7:05:00 AM ET
    $CTMX
    Biotechnology: Pharmaceutical Preparations
    Health Care